Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2013, Article ID 954956, 7 pages
http://dx.doi.org/10.1155/2013/954956
Review Article

Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status

1Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USA
2Albany Nephrology Pharmacy Group (ANephRx), Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, O'Brien 232, Albany, NY 12208, USA

Received 7 August 2012; Accepted 27 November 2012

Academic Editor: Alessandro Amore

Copyright © 2013 Natsuki Kubotera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Stenvinkel and A. Alvestrand, “Inflammation in end-stage renal disease: sources, consequences, and therapy,” Seminars in Dialysis, vol. 15, no. 5, pp. 329–337, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. T. A. Ikizler, R. L. Wingard, J. Harvell, Y. Shyr, and R. M. Hakim, “Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study,” Kidney International, vol. 55, no. 5, pp. 1945–1951, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. J. J. Carrero, A. R. Qureshi, J. Axelsson et al., “Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite,” The American Journal of Clinical Nutrition, vol. 85, no. 3, pp. 695–701, 2007. View at Google Scholar · View at Scopus
  4. B. R. Don and G. Kaysen, “Serum albumin: relationship to inflammation and nutrition,” Seminars in Dialysis, vol. 17, no. 6, pp. 432–437, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. D. S. Raj, J. J. Carrero, V. O. Shah et al., “Soluble CD14 Levels, Interleukin 6, and mortality among prevalent hemodialysis patients,” The American Journal of Kidney Diseases, vol. 54, no. 6, pp. 1072–1080, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Kalantar-Zadeh, G. Block, C. J. McAllister, M. H. Humphreys, and J. D. Kopple, “Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients,” The American Journal of Clinical Nutrition, vol. 80, no. 2, pp. 299–307, 2004. View at Google Scholar · View at Scopus
  7. T. A. Ikizler, L. B. Pupim, J. R. Brouillette et al., “Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation,” The American Journal of Physiology, vol. 282, no. 1, pp. E107–E116, 2002. View at Google Scholar · View at Scopus
  8. F. D. Vannini, A. A. Antunes, J. C. T. Caramori, L. C. Martin, and P. Barretti, “Associations between nutritional markers and inflammation in hemodialysis patients,” International Urology and Nephrology, vol. 41, no. 4, pp. 1003–1009, 2009. View at Publisher · View at Google Scholar
  9. S. D. Anker, P. Ponikowski, S. Varney et al., “Wasting as independent risk factor for mortality in chronic heart failure,” The Lancet, vol. 349, no. 9058, pp. 1050–1053, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. C. W. McIntyre, L. E. A. Harrison, M. T. Eldehni et al., “Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 1, pp. 133–141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Beutler and E. T. Rietschel, “Innate immune sensing and its roots: the story of endotoxin,” Nature Reviews Immunology, vol. 3, no. 2, pp. 169–176, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. R. A. Ward, “New AAMI standards for dialysis fluids,” Nephrology News & Issues, vol. 25, no. 13, pp. 33–36, 2011. View at Google Scholar
  13. K. Arizono, K. Nomura, T. Motoyama et al., “Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis,” Blood Purification, vol. 22, supplement 2, pp. 26–29, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Y. Hsu, C. L. Lin, C. C. Yu et al., “Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients: a prospective cross-over study,” Journal of Nephrology, vol. 17, no. 5, pp. 693–700, 2004. View at Google Scholar · View at Scopus
  15. U. Feroze, K. Kalantar-Zadeh, K. A. Sterling et al., “Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients,” Journal of Renal Nutrition, vol. 22, no. 3, pp. 317–326, 2012. View at Publisher · View at Google Scholar
  16. S. Genth-Zotz, S. von Haehling, A. P. Bolger et al., “Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure,” The American Journal of Cardiology, vol. 90, no. 11, pp. 1226–1230, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Gonclaves, R. Pecoits-Filho, and S. Perreto, “Fluid overload is associated with endotoxinemia but not with systemic inflammation in chronic kidney disease patients,” Journal of the American Society of Nephrology, vol. 16, p. 470A, 2005. View at Google Scholar
  18. M. C. Perianayagam and B. L. Jaber, “Endotoxin-binding affinity of sevelamer hydrochloride,” The American Journal of Nephrology, vol. 28, no. 5, pp. 802–807, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. P. P. Sun, M. C. Perianayagam, and B. L. Jaber, “Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study,” Journal of Renal Nutrition, vol. 19, no. 5, pp. 432–438, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. E. M. Stinghen, S. M. Gonçalves, S. Bucharles et al., “Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia,” Blood Purification, vol. 29, no. 4, pp. 352–356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. E. S. van Amersfoort, T. J. C. van Berkel, and J. Kuiper, “Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock,” Clinical Microbiology Reviews, vol. 16, no. 3, pp. 379–414, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. C. R. H. Raetz and C. Whitfield, “Lipopolysaccharide endotoxins,” Annual Review of Biochemistry, vol. 71, pp. 635–700, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Zanoni, R. Ostuni, G. Capuano et al., “CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation,” Nature, vol. 460, no. 7252, pp. 264–268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Zanoni, R. Ostuni, L. R. Marek et al., “CD14 controls the LPS-induced endocytosis of toll-like receptor 4,” Cell, vol. 147, no. 4, pp. 868–880, 2011. View at Publisher · View at Google Scholar
  25. A. B. Hauser, I. R. F. Azevedo, S. Gonçalves, A. Stinghen, C. Aita, and R. Pecoits-Filho, “Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia,” Blood Purification, vol. 30, no. 3, pp. 153–158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Noori, C. P. Kovesdy, R. Dukkipati et al., “Racial and ethnic differences in mortality of hemodialysis patients: role of dietary and nutritional status and inflammation,” The American Journal of Nephrology, vol. 33, no. 2, pp. 157–167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. K. A. Powers, A. Kapus, R. G. Khadaroo, G. Papia, and O. D. Rotstein, “25% albumin modulates adhesive interactions between neutrophils and the endothelium following shock/resuscitation,” Surgery, vol. 132, no. 2, pp. 391–398, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Kitano, H. Fukui, Y. Okamoto et al., “Role of albumin and high-density lipoprotein as endotoxin-binding proteins in rats with acute and chronic alcohol loading,” Alcoholism Clinical and Experimental Research, vol. 20, no. 1, supplement, pp. 73A–76A, 1996. View at Google Scholar · View at Scopus
  29. P. Kotanko, M. Carter, and N. W. Levin, “Intestinal bacterial microflora—a potential source of chronic inflammation in patients with chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 21, no. 8, pp. 2057–2060, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. L. A. Ding and J. S. Li, “Gut in diseases: physiological elements and their clinical significance,” World Journal of Gastroenterology, vol. 9, no. 11, pp. 2385–2389, 2003. View at Google Scholar · View at Scopus
  31. A. Krack, R. Sharma, H. R. Figulla, and S. D. Anker, “The importance of the gastrointestinal system in the pathogenesis of heart failure,” European Heart Journal, vol. 26, no. 22, pp. 2368–2374, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. J. Bullen, H. J. Rogers, P. B. Spalding, and C. G. Ward, “Iron and infection: the heart of the matter,” FEMS Immunology and Medical Microbiology, vol. 43, no. 3, pp. 325–330, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. J. R. Boelaert, R. F. Daniels, M. L. Schurgers, E. G. Matthys, B. Z. Gordts, and H. W. van Landuyt, “Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study,” Nephrology Dialysis Transplantation, vol. 5, no. 2, pp. 130–134, 1990. View at Google Scholar · View at Scopus
  34. T. Walter, M. Olivares, F. Pizarro, and C. Muñoz, “Iron, anemia, and infection,” Nutrition Reviews, vol. 55, no. 4, pp. 111–124, 1997. View at Google Scholar · View at Scopus
  35. H. Ashrafian, “Hepcidin: the missing link between hemochromatosis and infections,” Infection and Immunity, vol. 71, no. 12, pp. 6693–6700, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. K. J. Robson, “Hepcidin and its role in iron absorption,” Gut, vol. 53, no. 5, pp. 617–619, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. A. B. Pai, J. Depczynski, M. P. Pai, C. R. McQuade, and R. C. Mercier, “Non-transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose,” The American Journal of Nephrology, vol. 26, no. 3, pp. 304–309, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. D. S. C. Raj, V. O. Shah, M. Rambod, C. P. Kovesdy, and K. Kalantar-Zadeh, “Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis,” The American Journal of Kidney Diseases, vol. 54, no. 6, pp. 1062–1071, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Terawaki, K. Yokoyama, Y. Yamada et al., “Low-grade endotoxemia contributes to chronic inflammation in hemodialysis patients: examination with a novel lipopolysaccharide detection method,” Therapeutic Apheresis and Dialysis, vol. 14, no. 5, pp. 477–482, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Wanner, C. Drechsler, and V. Krane, “C-reactive protein and uremia,” Seminars in Dialysis, vol. 22, no. 4, pp. 438–441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Kumar, C. Haery, and J. E. Parrillo, “Myocardial dysfunction in septic shock,” Critical Care Clinics, vol. 16, no. 2, pp. 251–287, 2000. View at Google Scholar · View at Scopus
  42. O. Wrong and C. Harland, “Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure,” Nephron Physiology, vol. 107, no. 1, pp. 17–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. M. M. Barna, T. Kapoian, and N. B. O'Mara, “Sevelamer carbonate,” Annals of Pharmacotherapy, vol. 44, no. 1, pp. 127–134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. Genzyme Corporation, Renagel (Sevelamer Hydrochloride) Package Insert, Genzyme Corporation, Cambridge, Mass, USA, 2011.
  45. Genzyme Corporation, Renvela (Sevelamer Carbonate) Package Insert, Genzyme Corporation, Cambridge, Mass, USA, 2011.
  46. W. Braunlin, E. Zhorov, A. Guo et al., “Bile acid binding to sevelamer HCl,” Kidney International, vol. 62, no. 2, pp. 611–619, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. A. B. Pai and B. M. Shepler, “Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications,” Pharmacotherapy, vol. 29, no. 5, pp. 554–561, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. V. Autissier, S. J. P. Damment, and R. A. Henderson, “Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride,” Journal of Pharmaceutical Sciences, vol. 96, no. 10, pp. 2818–2827, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. J. F. Navarro-González, C. Mora-Fernández, M. M. de Fuentes, J. Donate-Correa, V. Cazaña-Pérez, and J. García-Pérez, “Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 9, pp. 2272–2279, 2011. View at Publisher · View at Google Scholar
  50. H. Vlassara, J. Uribarri, W. Cai et al., “Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 6, pp. 934–942, 2012. View at Publisher · View at Google Scholar
  51. W. N. Suki, “Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial,” Journal of Renal Nutrition, vol. 18, no. 1, pp. 91–98, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Di Iorio, A Bellasi, and D. Russo, “Mortality in kidney disease patients treated with phosphate binders: a randomized study,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 3, pp. 487–493, 2012. View at Publisher · View at Google Scholar